RC
AVIR icon

Rangeley Capital’s Atea Pharmaceuticals AVIR Stock Holding History

Rangeley Capital’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202K Sell
43,500
-3,000
-6% -$14.9K 0.18% 120
2026
Q1 		$250K Sell
46,500
-33,500
-42% -$154K 0.24% 84
2025
Q4 		$286K Hold
80,000
– – 0.24% 73
2025
Q3 		$232K Buy
80,000
+27,000
+51% +$92.2K 0.2% 84
2025
Q2 		$191K Buy
+53,000
New +$158K 0.23% 50

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rangeley Capital's AVIR Position: Q2 2026 in Review

Rangeley Capital reduced its Atea Pharmaceuticals (AVIR) stake by 6.5% in Q2 2026, selling an estimated $14.9K and leaving 43,500 shares worth $202K. The position accounts for 0.18% of the portfolio, ranked #120.

Rangeley Capital first reported a position in AVIR in Q2 2025 and has held it in 5 quarters since. The position peaked at $286K in Q4 2025. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Rangeley Capital held 43,500 shares of Atea Pharmaceuticals worth $202K as of Q2 2026.
  • Rangeley Capital sold 3,000 Atea Pharmaceuticals shares in Q2 2026, an estimated $14.9K.
  • Atea Pharmaceuticals made up 0.18% of Rangeley Capital's portfolio in Q2 2026, its #120 holding.
  • Rangeley Capital first reported a position in Atea Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Rangeley Capital's Atea Pharmaceuticals position peaked at $286K in Q4 2025.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.